Grand Medical Group

About us

Grand Medical Group AG is a group of pharmaceutical companies specialized in the development, production, registration and introduction into medical practice of modern innovative products based on organic, synthetic and herbal compounds.

read more

10 Kornmarkt Street, CH - 6004 Luzern, Switzerland

info@grandmedicalgroup.ch

+41 415880810

1 tablet contains 2.5 mg naratriptan, ?4

PHARMACOLOGIC PROPERTIES

ATC code: N02CC02, Selective 5-HT1 receptor agonists
Naratriptan has been shown to be a selective agonist for 5 hydroxytryptamine1 (5-HT1) receptors mediating vascular contraction. This receptor is found predominantly in intracranial (cerebral and dural) blood vessels. Naratriptan has high a?nity for human cloned 5-HT1B and 5-HT1D receptors; the human 5-HT1B receptor is thought to correspond to the vascular 5-HT1 receptor mediating contraction of intracranial blood vessels. Naratriptan has little or no e?ect at other 5-HT receptor (5-HT2, 5-HT3, 5-HT4 and 5-HT7) subtypes. The causes of migraine are not clearly understood; however, the e?cacy of naratriptan is believed to be due to their activity as 5HT (serotonin) agonists.

THERAPEUTIC INDICATIONS

NARANSI tablets are indicated for the acute treatment of migraine attacks with or without aura.

LEAFLETS